10-K: Stemtech Corporation Reports Reduced Net Loss Amidst Going Concern Doubts and Internal Control Weaknesses in 2024 Annual Filing

Stemtech Corporation's latest 10-K filing reveals a reduced net loss and improved operating cash flow for 2024, yet highlights significant financial challenges including a substantial accumulated deficit, working capital deficiency, and material weaknesses in internal controls, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net sales increased by 2.68% to $5,053,690 in 2024, up from $4,921,531 in 2023, primarily due to a slight increase in Independent Business Partners (IBPs).
• Total operating expenses decreased significantly by 24.93% to $6,113,773 in 2024, down from $8,144,439 in 2023, driven by effective cost management initiatives, including a reduction in general and administrative expenses.
• Net loss improved to $(3,772,701) in 2024 from $(5,431,979) in 2023, a year-over-year improvement of $1,659,278.
• Interest expense decreased substantially to $1,579,370 in 2024 from $4,893,033 in 2023, reflecting improved debt management and reduced financing costs.
• Current assets increased to $921,746 as of December 31, 2024, from $400,710 as of December 31, 2023, indicating an improvement in liquidity.
• Net cash used in operating activities significantly reduced to $(601,198) in 2024 from $(2,036,012) in 2023.
• The company reported an accumulated deficit of approximately $30.8 million and a working capital deficiency of approximately $8.1 million as of December 31, 2024.
• Management concluded that internal controls over financial reporting were not effective as of December 31, 2024, citing material weaknesses including the lack of an independent audit committee, no audit committee financial expert, insufficient segregation of duties, and inadequate written policies and procedures.
• Stemtech entered into a Merger Agreement with Seacret Direct, LLC on November 30, 2024, to acquire substantially all assets in exchange for 13,400,000 Preferred Shares valued at $2.50 per share, convertible into 10 Common Shares each.
• The company continues to face a lawsuit from its former CEO for approximately $267,000 in unpaid salary and vacation pay, which remains ongoing.

Sentiment

Score: 3

Explanation: While there are some positive operational improvements like reduced net loss and operating expenses, the severe going concern warning, substantial accumulated deficit, working capital deficiency, and critical internal control weaknesses present significant financial instability and high risk. The reliance on future dilutive financing further dampens the outlook, outweighing the modest revenue growth and new product introductions.

Positives

• Net sales increased by $132,159 (2.68%) in 2024, reaching $5,053,690, indicating growth in overall sales.
• Total operating expenses decreased significantly by $2,030,664 (24.93%) in 2024, primarily due to effective cost management initiatives and a reduction in general and administrative expenses.
• Net loss improved by $1,659,278 in 2024, reflecting better financial performance compared to the prior year.
• Interest expense decreased substantially from $4,893,033 in 2023 to $1,579,370 in 2024, indicating improved debt management and lower financing costs.
• Current assets increased to $921,746 in 2024 from $400,710 in 2023, showing an improvement in liquidity.
• Net cash used in operating activities significantly reduced from $(2,036,012) in 2023 to $(601,198) in 2024, indicating a more efficient use of cash in core operations.
• The company is a pioneer in stem cell science and holds multiple patents for its products, including US 9,289,375, AU 201127647, MX 344304, US 10,159,705, and MX 358857.
• New skincare products, Cellect One Rapid Renew Stem Cell Peptide Night Cream (December 2022) and Cellect One Shield HOCL (January 2025), have been introduced.
• Plans to introduce StemPets, a pet supplement, in April 2025, targeting the large global pet industry.
• Management believes sales can be reinvigorated to historical levels, noting the company's recognition four times in the Inc 5000 list of fastest-growing companies.
• Robust cybersecurity measures are in place, including FMA/2FA, email banners for external emails, and conditional access policies, with no material cybersecurity incidents reported to date.

Negatives

• The company has experienced recurring net losses and negative cash flows from operations since inception.
• An accumulated deficit of approximately $30.8 million and a working capital deficiency of approximately $8.1 million as of December 31, 2024, raise substantial doubt about the company's ability to continue as a going concern.
• Current liabilities increased to $9,009,049 as of December 31, 2024, from $6,462,036 at December 31, 2023, primarily driven by financing obligations and trade-related payables.
• Stockholders deficit increased to $(5,226,804) as of December 31, 2024, from $(2,778,765) as of December 31, 2023, primarily due to the net loss incurred.
• The company is not yet profitable and cannot provide assurance of when it will be profitable.
• Management concluded that internal controls over financial reporting were not effective as of December 31, 2024, due to material weaknesses.
• Material weaknesses in internal control include the lack of an independent audit committee, no audit committee financial expert, insufficient segregation of duties, and insufficient written policies and procedures for accounting and financial reporting.
• The company currently does not carry a cyber liability insurance policy, which could expose it to significant financial impact from a cybersecurity breach.
• Trading in the company's common stock is subject to penny stock rules, which may discourage broker-dealers and limit market price and liquidity.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses, negative cash flows from operations, an accumulated deficit of approximately $30.8 million, and a working capital deficiency of approximately $8.1 million.
• The company will require substantial additional funds to meet long-term operating requirements and implement new investment acquisition plans.
• Future issuances of equity or convertible debt securities will result in dilution to current shareholders.
• Terms of future securities issued may be more favorable for new investors, potentially including preferences, superior voting rights, and derivative securities with additional dilutive effects.
• The company may incur substantial costs (investment banking, legal, accounting fees) in pursuing future capital and financing.
• Non-cash expenses may be recognized in connection with certain securities (e.g., convertible notes, warrants), adversely impacting financial condition.
• Ability to obtain needed financing may be impaired by capital markets, generally and specifically in the nutraceutical industry.
• If adequate funds are not available on acceptable terms, the company may not be able to take advantage of new business endeavors or opportunities, or may be required to cease operations.
• An actual or perceived breach of cybersecurity could damage reputation, cause existing Independent Business Partners/customers to discontinue, prevent attraction of new clients, and/or lead to third-party lawsuits, regulatory fines, or other liabilities.
• The company does not currently carry a cyber liability insurance policy, increasing financial exposure to cybersecurity incidents.
• Ongoing legal proceeding with a former CEO alleging $267,000 in unpaid salary and vacation pay, which could result in a financial liability.
• The application of penny stock rules may affect the ability to resell the company's securities due to additional burdens on broker-dealers.

Future Outlook

Management expects to require additional capital to meet long-term operating requirements and plans to raise funds through the sale of equity or debt securities. The company anticipates additional increases in operating expenses and capital expenditures related to inventory acquisition, developmental expenses for a start-up business, and marketing expenses. It intends to finance these through further issuances of securities and director loans, acknowledging that additional equity or convertible debt will result in dilution for current shareholders. The company also plans to introduce 'StemPets' in April 2025, targeting the global pet industry, and aims to reinvigorate sales to be consistent with historical revenue levels.

Management Comments

• "Management conservatively believes we can reinvigorate sales to be more consistent with the company's previous revenue historically, as Stemtech has been recognized 4 times in the Inc 5000 Magazines list of fastest growing companies."
• "We expect we will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities."
• "We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of equity securities and debt instruments."
• "We will have to raise additional funds in the next twelve months in order to sustain and expand our operations."
• "We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the form of equity financing from the sale of our common stock."
• "We have and will continue to seek to obtain short-term loans from our directors, although no future arrangement for additional loans has been made."
• "We do not have any agreements with our directors concerning these loans."
• "We do not have any arrangements in place for any future equity financing."
• "Management believes the cost related to retaining a financial expert at this time is prohibitive."
• "Stemtech's Board of Directors has determined that it does not presently need an audit committee financial expert on the Board of Directors to carry out the duties of the Audit Committee."
• "Stemtech's Board of Directors has determined that the cost of hiring a financial expert to act as a director of Stemtech and to be a member of the Audit Committee or otherwise perform Audit Committee functions outweighs the benefits of having a financial expert on the Audit Committee."

Industry Context

Stemtech operates in the global network marketing and nutraceutical industry, specializing in stem cell nutrition products. The company's direct sales model, leveraging Independent Business Partners (IBPs) and a Direct-To-Consumer (DTC) approach, positions it at the intersection of the e-commerce, social, and gig economies. The planned expansion into the pet supplement market with 'StemPets' indicates an attempt to diversify within the broader wellness sector and tap into the significant $303 billion global pet industry. The company's historical recognition in the Inc 5000 suggests past growth potential, but its current financial challenges, including recurring losses and a going concern warning, indicate it is struggling to maintain competitive health and profitability within its industry, especially compared to more established or better-capitalized players.

Comparison to Industry Standards

• The company's recurring net losses and significant accumulated deficit of $30.8 million are well below industry standards for a healthy, growing nutraceutical or direct sales company, which typically aim for profitability and positive retained earnings.
• The working capital deficiency of $8.1 million indicates severe short-term liquidity issues, a stark contrast to financially stable companies in the industry that maintain positive working capital to fund operations and growth.
• The reliance on continuous equity and debt financing, with explicit warnings of dilution, is a common characteristic of early-stage or distressed companies, not a standard for mature, self-sustaining businesses in the health and wellness sector.
• The material weaknesses in internal control over financial reporting, including the lack of an independent audit committee and financial expert, fall significantly short of corporate governance best practices and SEC compliance expectations for publicly traded companies, regardless of their size.
• While the company's sales increased, the overall financial health and operational efficiency, as evidenced by the going concern warning, suggest it is underperforming compared to industry peers that have achieved sustainable profitability and robust financial controls.

Management Changes

Corporate Governance

Legal Proceedings

• An ongoing lawsuit filed on August 6, 2019, by the former CEO (prior to the company's bankruptcy proceedings) against Stemtech HealthSciences Corp., alleging unpaid salary and vacation pay totaling approximately $267,000. The company has filed a counterclaim and considers the claims without merit. As of December 31, 2024, the company has accrued $267,000 related to this matter. The Court dismissed the former CEO's request for summary judgment on March 3, 2023, but the litigation continues.

Related Party Transactions

• John W. Meyer, President and COO, provided a loan of $105,000 to the company during 2024.
• On March 19, 2024, the company issued 900,000 shares of common stock to the Chief Financial Officer as stock-based compensation, valued at $45,000.
• On March 19, 2024, the company issued an aggregate of 5,000,000 shares of common stock to five directors (1,000,000 each) as stock compensation, valued at $150,000.
• The company recognized $440,256 in stock compensation expense during 2024 related to awards previously granted to its Chairman and CEO.
• As of December 31, 2024, the company owed outstanding principal balances of convertible promissory notes totaling $106,009 to Chief Operating Officer and President Mr. John W. Meyer and $25,000 to Director Mr. Darryl V. Green.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from anticipated future equity raises, as well as potential loss of investment due to the substantial doubt about the company's ability to continue as a going concern. The increase in authorized shares to 400 million further enables dilution. The penny stock rules may limit liquidity and market price for existing shareholders.
• **Employees:** The company has reduced its labor force as part of cost-cutting measures, which could impact employee morale and job security. Stock-based compensation is a significant part of executive and director compensation, aligning their interests with share performance but also exposing them to share price volatility.
• **Customers/Independent Business Partners (IBPs):** The company's financial instability and going concern warning could impact product availability, customer service, and the long-term viability of the business opportunity for IBPs. Cybersecurity risks could also lead to data breaches affecting customer and IBP information.
• **Creditors:** Current liabilities increased significantly, and the company relies heavily on debt financing, including related-party loans and factoring arrangements, increasing risk for creditors if the company's financial health does not improve.
• **Suppliers:** The increase in accounts payable and accrued expenses suggests potential pressure on supplier payments, which could strain relationships and impact supply chain reliability.

Next Steps

• Raise additional capital through equity or debt securities to meet long-term operating requirements and fund business plan.
• Acquire inventory, incur developmental expenses for start-up business, and increase marketing expenses.
• Introduce 'StemPets' pet supplement in April 2025.
• Complete the audit of Seacret Direct, LLC and satisfy other customary closing conditions for the merger agreement.
• Address material weaknesses in internal control over financial reporting, including establishing an independent audit committee, appointing a financial expert, improving segregation of duties, and developing written policies and procedures.

Key Dates

Recommendation

Keywords

Stemtech Corporation, STEK, 10-K, Annual Report, SEC filing, financial performance, net loss, operating expenses, revenue growth, going concern, liquidity, capital raise, dilution, internal controls, material weaknesses, corporate governance, nutraceuticals, stem cell nutrition, network marketing, direct sales, cybersecurity, legal proceedings, penny stock, Seacret Direct, merger agreement, debt management